ArQule Says Partner Halts Cancer Drug Trial, Shares Slide

Biotechnology company ArQule said Japan’s Kyowa Hakko Kirin Co, which holds development rights to an ArQule cancer drug in parts of Asia, suspended patient enrollment in a late-stage trial to treat lung cancer.
Reuters